Accrual for Seamless has been slow, but should now accelerate as more centers have been added. The 2nd DMSB review was favorable. DMSB for futility occurs after 212 patients have been enrolled and that should be within the year, and will add value if positive.. Follow up on the MDS data would be well presented in the context of ASCO in mid May, but may be sooner. Still a lot of pluses for a biotech with a tiny market cap and the potential for a big pop with any favorable development.
Read the transcript again. 38% of patient population was 75 and older. Historically, patients 70 and older only have an overal survivability of 3.6 months. With SEAMLESS shows that treatment in that age group have a current median OS of 9.4 months. The hardest age group to treat has almost a 3 times greater life expectancy only by taking pills without the miserable injections, chemo, etc. that causes your hair to fall out, mouth sores, nausean, etc. etc. etc. That's no quality of life replaced by an oral therapy that is highly tolerated. And the patient population continues to live longer so revised OS still to come. Or did I read the transcript wrong?